Dr. Judice currently serves as the co-founder and chief executive officer at DiCE Molecules. Prior to DiCE Molecules, Dr. Judice served as chief scientific officer at Cidara Therapeutics, an antifungal company he helped found in 2012. In 2004, Dr. Judice co-founded Achaogen, Inc. (Nasdaq: AKAO), where, as the first employee, he was the chief scientific officer and chief executive officer. During his seven-year tenure at Achaogen, he oversaw three rounds of venture financing, steered its growth to 65 full-time employees and established collaborations with DARPA, NIAID, DTRA and BARDA. Prior to Achaogen, Dr. Judice served as the vice president of chemistry at Theravance, where he led the discovery of Vibativ (televancin).
Dr. Judice received his Ph.D. in organic chemistry from the University of California Los Angeles and did his postdoctoral fellowship at the University of California Berkeley. He received his Bachelor of Science in chemistry from Texas A&M University. Dr. Judice is also a Henry Crown Fellow at the Aspen Institute.
Phil Patten, PhD
Founder & Chief Scientific Officer
Dr. Patten joined DiCE Molecules as chief scientific officer in May 2014. Prior to DiCE Molecules, Dr. Patten served at Pioneer HiBred, where he was a DuPont Fellow, research director and led a team of 90 scientists doing directed evolution of proteins and large-scale synthetic biology in the agricultural space. Prior to Pioneer HiBred, Dr. Patten served as senior vice president of biology at Achaogen, where he led the DTRA-funded LpxC program to the discovery of ACHN-975, a small molecule now in Phase 1b with several backup clinical compounds. In addition, he also served as vice president of technology at Maxygen, a pioneer in the field of directed protein evolution via gene shuffling. While at Maxygen, he led the team that produced an improved gene shuffled interferon alpha that entered clinical trials. He is also a named inventor on an evolved herbicide tolerance gene (GAT) that is in late-stage commercial development.
Dr. Patten has been actively involved in the practice of directed evolution since the inception of the field in the early 1980s and he holds more than 80 granted patents in this field. He received his Ph.D. in biology from Stanford University and conducted his postdoctorate education in chemistry at the University of California Berkeley. He received his Bachelor of Science degree in biology from CalTech.
John Jacobsen, PhD
Vice President, Chemistry
Dr. Jacobsen joined DiCE Molecules in November 2015 as vice president of chemistry where he is responsible for the design, development and execution of on-DNA chemistry to build and evaluate chemical libraries. Prior to DiCE Molecules, Dr. Jacobsen was at Theravance Biopharma (formerly Theravance, Inc.) for 18 years, most recently serving as senior director of medicinal chemistry. At Theravance, Dr. Jacobsen led three research programs in respiratory disease and helped transition six compounds into early development. As a member of the Theravance-GlaxoSmithKline Joint Project Committee (JPC), he helped advance collaboration assets through clinical trials to FDA approvals of Breo® and Anoro®. Within the medicinal chemistry department, he had line-management responsibility for as many as three medicinal chemistry teams, as well as the high-throughput purification group.
Dr. Jacobsen holds an A.B. in Chemistry from Harvard College and a Ph.D. in Organic Chemistry from the University of California, Berkeley.
Chief Financial Officer
Mr. Robertson is currently Chief Financial Officer at DiCE Molecules. Prior to DiCE Molecules, Mr. Robertson served at DuPont where he was Business Development Director for DuPont Pioneer with responsibility for the business unit’s crop genetics and precision agriculture M&A activity. He also held the position of portfolio manager with DuPont Ventures where he focused on strategic investment opportunities in production agriculture and the intersection of agriculture and downstream renewable technologies. Prior to joining DuPont, Mr. Robertson was an investment professional at MPM Capital, a life sciences-dedicated venture capital fund, and previous to that a member of the Healthcare Investment Banking groups at Merrill Lynch & Co. and Thomas Weisel Partners. He received a Bachelor of Science in Business Administration from the University of Southern California and an M.B.A. from the Haas School of Business at the University of California, Berkeley.
Richard Scheller, PhD
Chairman of the Board
Prior to becoming Chairman of the Board at DiCE Molecules in late 2015, Dr. Scheller had joined 23andMe in January 2015 as Chief Scientific Officer and Head of Therapeutic Development. There, he is responsible for translating genetic information into new therapies.
Hired in 2001 as Senior Vice President of Research and member of the Genentech Executive Committee, from 2009 through 2014, he was Executive Vice President and Head of Genentech Research and Early Development, and a member of the Roche Executive Committee. Dr. Scheller received his Bachelor of Science in biochemistry in 1975 from the University of Wisconsin–Madison and his doctorate in chemistry in 1980 from Caltech. After postdoctoral fellowships at Caltech and Columbia, Dr. Scheller joined the Stanford faculty from 1982 until 2001. An investigator with the Howard Hughes Medical Institute from 1994 to 2001, Dr. Scheller has been an adjunct professor at UC San Francisco since 2004. In 2014, he was named a trustee of Caltech.
Dr. Scheller’s research elucidating molecular mechanisms governing neurotransmitter release earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience, and the 1997 US National Academy of Sciences Award in Molecular Biology. He is a Fellow of the American Academy of Arts and Sciences, and a member of the National Academy of Sciences and the National Academy of Medicine.
John Bedbrook, PhD
Founder & Member of the Board
Dr. Bedbrook is a founder and Member of the DiCE Molecules Board of Directors. Dr. Bedbrook also serves as vice president of research and development, DuPont Agriculture & Nutrition of EI DuPont De Nemours & Co. Dr. Bedbrook joined DuPont in July 2004 through the acquisition of Verdia Inc. by Pioneer. He was chief executive officer and director of Verdia Inc. and its president from March 2002 to July 2004. He joined Maxygen Inc. as president of Agriculture in November 1999. Before joining Maxygen, Dr. Bedbrook served as chief executive officer of Plant Science Ventures and was chief technology officer at SAVIA from February 1998 to October 1999. Before joining SAVIA, Dr. Bedbrook held several senior management positions, including executive vice president of research and development and co-president at DNA Plant Technology Corp. from 1988 to 1997 and also served as director, science. He was founder and served as vice president of research at Advanced Genetic Sciences Inc.
Dr. Bedbrook earned his Ph.D. in molecular biology from the University of Auckland New Zealand. He was a Fulbright Scholar to Harvard Medical School and held a Jane Coffin Childs Fellowship to Harvard University. He was also a Cabot Fellow at Harvard University and an EMBO Fellow to the Plant Breeding Institute in Cambridge, England.
Pehr Harbury, PhD
Founder, Member of the Board & Chairman - Scientific Advisory Board
Dr. Harbury holds the position of Associate Professor of Biochemistry at the Stanford School of Medicine. He is a pioneer in the field of DNA-encoded organic synthesis and was honored with a prestigious MacArthur genius award for his work in this field. He is a recipient of the ASBMB Young Investigator Award for outstanding contributions in biochemistry and molecular biology, and an NIH Director’s Pioneer Award. His laboratories at Stanford have produced the prototypical DiCE Works instrumentation and protocols. Dr. Harbury is a Founder, Member of the Board, and Chairman – Scientific Advisory Board.
Dr. Harbury received his Ph.D. in chemistry and chemical biology from Harvard University. He also conducted his postdoctoral fellowship at the University of California Berkeley.
Stephen Zachary, PhD
Stephen Zachary is a Principal at Sands Capital Ventures, a venture capital firm based in the Washington DC area. At Sands Capital, Stephen leads private life sciences investments in therapeutic, diagnostic, and life sciences tools businesses. Prior to joining Sands Capital, Stephen received his PhD in neuroscience from Johns Hopkins School of Medicine. Stephen served as Director of Business Development and Research Analytics at Agilis Biotherapeutics, a gene therapy company focused on rare neurological diseases, and is a Kauffman Fellow (Class 23).
Michael P. Rubin, MD, PhD
Michael P. Rubin, M.D., Ph.D. is the founder and CEO of Northpond Ventures, a formative stage venture-capital fund dedicated to science and technology. Dr. Rubin’s active directorships include Mitra Biotech, Selux Diagnostics, NanoView Biosciences, GALT, and DiCE Molecules.
Dr. Rubin was previously co-founder and managing partner of Sands Capital Ventures, a global cross industry venture capital business, and affiliate of Sands Capital Management. Under Dr. Rubin’s leadership, SCV invested in dozens of leading startups, resulting in numerous successful businesses and exits, including DocuSign (IPO), Mulesoft (IPO; sale to Salesforce), AppDynamics (sale to Cisco), Dova (IPO), Paydiant (sale to PayPal), Quad Technologies (sale to Biotechne), Firefly Bioworks (sale to Abcam), and Agilis (Sale to PTC Therapeutics).
Dr. Rubin became a board certified physician and surgeon, and completed his fellowship training at Harvard Medical School. Dr. Rubin has led multiple IRB-approved research groups, published numerous papers in refereed journals, written chapters in leading texts, conducted clinical trials on leading commercial molecules, received NIH funding for novel research, attained industry sponsored funding for original biotherapeutic investigations, presented studies at large international forums, and conducted basic science research in molecular genetics at Harvard’s Ocular Genetics Institute. Dr. Rubin also holds an MBA from The University of Massachusetts Amherst, is a CFA charterholder, earned his medical doctorate at The University of Chicago, and holds a BS in Electrical Engineering from The UCLA Samueli School of Engineering, where he was the student graduation speaker.